(Q35962019)

11 August 2017

1 reference

title

Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting (English)

1 reference

11 August 2017

1 reference

Alison M Massaro

1

1 reference

11 August 2017

Kristi L Lenz

series ordinal

2

1 reference

11 August 2017

language of work or name

English

0 references

publication date

23 November 2004

1 reference

Annals of Pharmacotherapy

11 August 2017

published in

1 reference

11 August 2017

volume

39

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

77-85

1 reference

11 August 2017

cites work

Cancer statistics, 2004

1 reference

Proposal for classifying the acute emetogenicity of cancer chemotherapy

21 January 2018

1 reference

Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Instit

21 January 2018

1 reference

A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.

21 January 2018

1 reference

Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treate

21 January 2018

1 reference

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

21 January 2018

1 reference

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

21 January 2018

1 reference

The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog.

21 January 2018

1 reference

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

21 January 2018

1 reference

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

21 January 2018

1 reference

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

21 January 2018

1 reference

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

21 January 2018

1 reference

Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant

21 January 2018

1 reference

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.

21 January 2018

1 reference

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

21 January 2018

1 reference

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

21 January 2018

1 reference

Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects

21 January 2018

1 reference

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

21 January 2018

1 reference

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

21 January 2018

1 reference

Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity

21 January 2018

1 reference

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E242

1 reference

11 August 2017

1 reference